

FACT SHEET — AT A GLANCE

WHAT IT IS	A diagnostic-support tool that reads chest X-rays for signs of disease and flags regions for a clinician's review. It supports the clinician; it never replaces them.
WHAT IT DETECTS	Cardiomegaly, pleural effusion, consolidation. Three findings — stated openly.
REGULATORY STATUS	PENDING Awaiting NAFDAC clearance as a diagnostic-support medical device. Not yet cleared for clinical use.
CLINICAL STATUS	BETA Entering clinical beta with a partner clinic (September 2026). No general deployment yet.
THE ARCHITECTURE	DRF-MWU — a hybrid transformer constrained by deterministic architectural rules. It reads by region, is traceable per cell rather than as a heatmap, and is structurally unable to hallucinate. Held as a trade secret .
AT BASELINE	Zero parameters at rest — pure architecture. It takes on a domain from a few hundred films, not hundreds of thousands, and calibrates to the local population on deployment.
RUNS WHERE	On the device, offline. The read needs no internet, cloud, or GPU. Cloud-connected features (copilot, longitudinal tracking, grid updates) reach Google Cloud and Gemini.
PATIENT DATA	No patient image ever leaves the device. Only the engine's numeric vectors and tensors sync — an X-ray cannot be reconstructed from them, nor traced to a patient. Accounts are encrypted.
HOW IT IMPROVES	The treating clinician confirms or corrects each read; that feedback trains the engine and stands up the public Master Grid for the region — benefiting every nearby clinic.
BUSINESS MODEL	Bulk usage credit (\$1.75/scan entry, \$2.20 global), spent on reads or the copilot. Pro fleet accounts add \$80/device/month; a custom Master Grid adds \$300/month. Small and rural clinics use a free tier.
BUILT BY	GeoRadX AI Diagnostics Ltd (Abuja, Nigeria). The core engine was built from first principles by a single researcher; the company is run by a small team.
FIRST MARKET	Mobile NGO and public-health screening across West Africa, where the radiologist shortage is most acute — then other under-served regions.

GeoRadX is a diagnostic-support tool — not a replacement for professional medical judgment. Pending regulatory approval; not yet cleared for clinical use. Figures and status current as of the date of issue and subject to change.